Abstract
The introduction of CF promises to be an important step towards a more successful treatment of colorectal cancer. CF (CH2-H4Pte Glu) is a biochemical modulator of fluoropyrimidine action and enhances cytotoxicity of FUra and FUDR in vitro and in vivo. CF/FUra combinations have been investigated in a number of clinical trials. Objective response rates of 30% – 40% were reproducibly achieved indicating a superiority of CF/FUra over FUra alone (1–7). However, inspite of these promising results the benefit of chemotherapy in colorectal cancer remains undetermined with respect to patient survival which is influenced by factors leading to a wide range of spontaneous survival time of patients with advanced colorectal cancer, e.g. stage of disease, tumor load, and particularly rate of tumor growth at time of diagnosis. If tumor growth rates are not determined prior to therapy treatment outcome might be biased by slowly or rapidly proliferating tumors and not necessarily reflect drug activity. Also, lack of tumor growth during observation period might be misinterpreted as antineoplastic effect (“no change”,“stabilisation”).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Laufman, L.R., Krzeczowski, K.A., Roach, R, and Segal, M., 1987, Leucovorin plus 5-Fluorouracil: an effective treatment for metastatic colon cancer, J. Clin. Oncol., 5: 1394–1400.
Cunningham, J., Bukowski, R.M., Budd, T.G., Weick, J.K., and Purvis, J., 1984, 5-fluorouracil and folinic acid: a phase i-II trial in gastrointestinal malignancy, Investigational New Drugs, 2: 391 – 395.
Machover, D., Goldschmidt, E., Chollet, P., Metzger, G., Zittoun, J., Marquet, J., Vandenbulcke, J.M., Misset, J.L., Schwarzenberg, L., Fourtillan, J.B., Gaget, H., and Mathé, G., 1986, Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high dose folinic acid, J. Clin. Oncol., 4: 685–696.
Zakem, M., Hines, J.D., Adelstein, D.J., and Rustum, Y.M., 1986, High-dose leukovorin and 5-fluorouracil (5-FU) in refractory and relapsed colo-rectal carcinoma, Proc. Am. Soc. Clin. Oncol., 5: 81 (abstr.).
Doroshow, J.H., Bertrand, M., Multhauf, P., Leong, L., Goldberg, D., Margolin, K., Carr, B., Akman, S., and Hill, R., 1987, Prospective randomized trial comparing 5-fluorouracil versus (vs) 5-FU and high dose folinic acid (HDFA) for treatment of advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 6: 96 (abstr.).
Petrelli, N., Herrera, L., Stulc, J., Rustum, Y.M., and Mittelman, A., 1987, A phase III study of 5-fluorouracil (5-FU) versus 5-FU + methotrexate (MTX) versus 5-FU + high dose leucovorin (CF) in metastatic colorectal adenocarcinoma. Proc. Am. Soc. Clin. Oncol., 6: 74 (abstr.).
Ehrlichman, C., Fine, S., Wong, A., et al., 1988, A randomized trial of 5-fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J. Clin. Oncol., in press.
Carter, S.D., 1976, Large bowel cancer: the current status of treatment, JNCI, 56: 3 – 10.
Moertel, C.G., 1978, Chemotherapy of gastrointestinal cancer, N. Engl. J. Med., 299: 1049–1052.
Radice, P.A., Bunn, P.A., and Ihde, D.C., 1979, Therapeutic trials with VP-16–213 and VM-26: active agents in small cell lung cancer, non-hodgkin’s lymphomas, and other malignancies. Cancer Treat. Rep., 63: 1231–1239.
Schmoll, H.-J., Niederle, N., and Achterrath, W., 1981, Etoposid (VP-16–213). Klin. Wochenschrift, 59: 1177–1188.
Dorr, R.T., and Fritz, W.L.,1980,5-Fluorouracil,in:“Cancer chemotherapy handbook,” R.T. Dorr, and W.L. Fritz, eds., Elsevier, New York, Amsterdam, Oxford.
Cocconi, G., DeLisi, V., and Blasio, B., 1982, Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat. Rep., 66: 1263–1266.
MacDonald, J.S., Gunderson, L.L.,and Cohn I.Jr., 1985, Cancer of the stomach, in: Cancer, principles and practise of oncology, V. T. DeVita, S. Hellman, and S.A. Rosenberg, eds., Lippincott, Philadelphia.
Kelsen, D.p., Magill, G., and Cheng, E., Phase II trial of Etoposide (VP-16) in the treatment of upper gastrointestinal malignancies. Proc. Am. Soc. Clin. Oncol.,123: 96 (abstr.)
Hill, B.T., 1986, Potential of continous tumor cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro, Drugs Exptl. Clin. Res., 12: 685–696.
Osswaldt, H., and Kunz, W., 1987, Therapeutic synergism of Etoposide and 5-fluorouracil combined sequentially in advanced leukemia L 1210, Cancer Res. Clin. Oncol., 113 (suppl.): 53 (abstr.)
Beretta, G., Fraschini,P., Labianca, R., Arnoldi, E., Pan-cera, G., Tedeschi, L., and Luporini, G., 1986, Weekly 5fluorouracil (F) versus combination chemotherapy for advanced gastrointestinal carcinomas, Proc. Am. Soc. Clin. Oncol., 5: 94 (abstr.).
Douglass, H.O.Jr., Lavin, P.T., Goudsmit, A., Klaasen, D. J., and Paul, A.R., 1984, An eastern cooperative oncology group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277 ), J. Clin. Oncol., 2: 1372–1381.
MacDonald, J.S., Schein, P.S., Wooley, P.V., Smythe, T., Ueno, W., Hoth, D., Smith, F., Boiron, M., Gisselbrecht, C., Brunet, R., and Lagarde, C., 1980, 5-Fluorouracil, doxorubicin, and mitomycin ( FAM) combination-chemotherapy for advanced gastric cancer, Ann. Int. Med., 93: 533–536.
Fornasiero, A., Cartei, G., Daniele, O., Fosser, V., and Fiorentino, M. V., 1984, FAM2 regimen in disseminated gastric cancer, Tumori, 70: 77 – 80.
MacDonald. J.S., Gunderson, L.L., and Cohn, I.Jr., 1985, Cancer of the stomach, in: Cancer, principles and practise of oncology, V. T. DeVita, S. Hellman, and S.A. Rosenberg, eds., Lippincott, Philadelphia.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Wilke, H. et al. (1988). Folinic Acid (CF)/5-Fluorouracil (FUra) Combinations in Advanced Gastrointestinal Carcinomas. In: Rustum, Y., McGuire, J.J. (eds) The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, vol 244. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-5607-3_25
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5607-3_25
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-5609-7
Online ISBN: 978-1-4684-5607-3
eBook Packages: Springer Book Archive